V. Rovei

733 total citations
42 papers, 588 citations indexed

About

V. Rovei is a scholar working on Analytical Chemistry, Pharmacology and Spectroscopy. According to data from OpenAlex, V. Rovei has authored 42 papers receiving a total of 588 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Analytical Chemistry, 10 papers in Pharmacology and 10 papers in Spectroscopy. Recurrent topics in V. Rovei's work include Analytical Methods in Pharmaceuticals (11 papers), Analytical Chemistry and Chromatography (10 papers) and Pharmacogenetics and Drug Metabolism (8 papers). V. Rovei is often cited by papers focused on Analytical Methods in Pharmaceuticals (11 papers), Analytical Chemistry and Chromatography (10 papers) and Pharmacogenetics and Drug Metabolism (8 papers). V. Rovei collaborates with scholars based in France, Italy and Belgium. V. Rovei's co-authors include P. L. Morselli, M. Mitchard, Roberto Goméni, F Chanoine, Alberto Frigerio, Pavel D. Hrdina, D. Caille, R A Braithwaite, C. Pantarotto and Christian Funck‐Brentano and has published in prestigious journals such as The British Journal of Psychiatry, Journal of Pharmacology and Experimental Therapeutics and Journal of Chromatography A.

In The Last Decade

V. Rovei

41 papers receiving 529 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. Rovei France	15	152	126	114	106	90	42	588
M. L. Jack United States	14	134 0.9×	87 0.7×	145 1.3×	187 1.8×	93 1.0×	15	762
Richard A. Okerholm United States	18	170 1.1×	129 1.0×	87 0.8×	59 0.6×	163 1.8×	36	842
O. Borg� Sweden	11	141 0.9×	83 0.7×	112 1.0×	92 0.9×	79 0.9×	18	533
Robert A. Ronfeld United States	18	236 1.6×	82 0.7×	148 1.3×	89 0.8×	147 1.6×	29	1.0k
Soong T. Chiang United States	17	306 2.0×	101 0.8×	106 0.9×	170 1.6×	93 1.0×	35	800
W Theobald Switzerland	16	255 1.7×	114 0.9×	92 0.8×	96 0.9×	171 1.9×	47	872
J.K. Cooper Canada	17	196 1.3×	180 1.4×	55 0.5×	92 0.9×	168 1.9×	61	778
J.P. Dubois Switzerland	12	88 0.6×	100 0.8×	56 0.5×	82 0.8×	66 0.7×	24	383
Carole Bye United Kingdom	16	150 1.0×	83 0.7×	86 0.8×	52 0.5×	79 0.9×	29	752
Lester C. Mark United States	18	112 0.7×	76 0.6×	116 1.0×	89 0.8×	136 1.5×	46	1.0k

Countries citing papers authored by V. Rovei

Since Specialization

Citations

This map shows the geographic impact of V. Rovei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Rovei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Rovei more than expected).

Fields of papers citing papers by V. Rovei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Rovei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Rovei. The network helps show where V. Rovei may publish in the future.

Co-authorship network of co-authors of V. Rovei

This figure shows the co-authorship network connecting the top 25 collaborators of V. Rovei. A scholar is included among the top collaborators of V. Rovei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Rovei. V. Rovei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Curet, O., et al.. (1996). Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile.. Journal of Pharmacology and Experimental Therapeutics. 277(1). 253–264. 18 indexed citations

Caille, D., et al.. (1996). Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.. Journal of Pharmacology and Experimental Therapeutics. 277(1). 265–277. 36 indexed citations

Rovei, V., et al.. (1994). Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor. PubMed. 41. 339–347. 9 indexed citations

Caille, D., et al.. (1994). Interaction of MAO inhibitors and dietary tyramine: A new experimental model in the conscious rat. Journal of Pharmacological and Toxicological Methods. 32(4). 219–224. 14 indexed citations

Rovei, V., et al.. (1993). Determination of antipyrine sulphoconjugates in isolated cultured rat hepatocytes. Xenobiotica. 23(2). 181–191. 6 indexed citations

Rovei, V., et al.. (1992). BEFLOXATONE, A NEW OXAZOLIDINONE REVERSIBLE MAO-A INHIBITOR. Clinical Neuropharmacology. 15. 425B–425B. 2 indexed citations

Ansseau, M., et al.. (1992). Phase I study of single ascending doses of befloxatone, a new reversible MAO-A inhibitor antidepressant. European Neuropsychopharmacology. 2(3). 300–300. 1 indexed citations

Funck‐Brentano, Christian, et al.. (1992). Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clinical Pharmacology & Therapeutics. 52(4). 384–393. 47 indexed citations

Barzaghi, N., et al.. (1989). PHARMACOKINETICS OF DEXTROMORAMIDE IN SURGICAL PATIENTS. Fundamental and Clinical Pharmacology. 3(1). 27–35. 7 indexed citations

10.

Rovei, V., et al.. (1988). The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis. European Journal of Clinical Pharmacology. 35(4). 391–396. 3 indexed citations

11.

Rovei, V., et al.. (1987). Pharmacokinetics of bendazac-lysine and 5-hydroxybendazac in patients with renal insufficiency. European Journal of Clinical Pharmacology. 33(3). 303–310. 2 indexed citations

12.

Rovei, V., et al.. (1985). Determination of low plasma concentrations of 3-methoxy-4-hydroxyphenylethylene glycol using gas chromatography—negative-ion chemical ionization mass spectrometry. Journal of Chromatography B Biomedical Sciences and Applications. 343(2). 239–247. 4 indexed citations

13.

Rovei, V., et al.. (1984). Reversed-phase high-performance liquid chromatographic separation of 14C-labelled toloxatone and its metabolites. Journal of Chromatography B Biomedical Sciences and Applications. 311(2). 329–337. 2 indexed citations

14.

Rovei, V., F Chanoine, M. Strolin Benedetti, Roland Zini, & J.P. Tillement. (1983). Plasma protein binding of the reversible type a MAO inhibitor cimoxatone (MD 780515). Biochemical Pharmacology. 32(15). 2303–2308. 5 indexed citations

15.

Rovei, V., et al.. (1982). Pharmacokinetics of theophylline: a dose‐range study.. British Journal of Clinical Pharmacology. 14(6). 769–778. 37 indexed citations

16.

Rovei, V., et al.. (1981). Quantitative determination of naproxen in plasma by a simple high-performance liquid chromatographic method. Journal of Chromatography B Biomedical Sciences and Applications. 224(1). 43–49. 22 indexed citations

17.

Assael, B.M., G. Avanzini, M. L. Caccamo, et al.. (1980). Plasma Levels and Clinical Effects of Antiepileptic Drugs in Pregnant Epileptic Patients and Their Newborns. Obstetrical & Gynecological Survey. 35(9). 561–562. 23 indexed citations

18.

Vereczkey, L., G. Bianchetti, V. Rovei, & Alberto Frigerio. (1976). Gas chromatographic method for the determination of nomifensine in human plasma. Journal of Chromatography A. 116(2). 451–456. 14 indexed citations

19.

Belvedere, G., V. Rovei, C. Pantarotto, & Alberto Frigerio. (1975). Identification of Cyclobenzaprine-10, 11-Epoxide and other Metabolites after Incubation of Cyclobenzaprine with Rat Liver Microsomes. Xenobiotica. 5(12). 765–771. 7 indexed citations

20.

Belvedere, G., V. Rovei, C. Pantarotto, & Alberto Frigerio. (1974). Mass spectrometric identification of anN-oxide formed by incubation ofN,N-dimethyl-5H-dibenzo[a,d]cycloheptene-Δ5,γ-propylamine with rat liver microsomes. Journal of Mass Spectrometry. 1(5). 329–331. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact